Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

BACKGROUND: Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drug's ability to prevent type 2 diabetes in individuals at high risk of developing the condition. METHODS: 5269 adults a...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Gerstein, H, Yusuf, S, Bosch, J, Pogue, J, Sheridan, P, Dinccag, N, Hanefeld, M, Hoogwerf, B, Laakso, M, Mohan, V, Shaw, J, Zinman, B, Holman, R
פורמט: Journal article
שפה:English
יצא לאור: 2006